CIC
NMTR

Carnegie Investment Counsel’s 9 Meters Biopharma NMTR Stock Holding History

Carnegie Investment Counsel’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$2K – 525
2022
Q3 		$2K Hold
500
– – ﹤0.01% 474
2022
Q2 		$3K Hold
500
– – ﹤0.01% 471
2022
Q1 		$6K Hold
500
– – ﹤0.01% 486
2021
Q4 		$10K Hold
500
– – ﹤0.01% 495
2021
Q3 		$13K Buy
+500
New +$11.8K ﹤0.01% 468

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Carnegie Investment Counsel's NMTR Position: Q4 2022 in Review

Carnegie Investment Counsel sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 500 shares — an estimated $2K sold.

Carnegie Investment Counsel first reported a position in NMTR in Q3 2021 and held it in 5 quarters. The position peaked at $13K in Q3 2021. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • Carnegie Investment Counsel reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • Carnegie Investment Counsel sold 500 9 Meters Biopharma shares in Q4 2022, an estimated $2K.
  • Carnegie Investment Counsel first reported a position in 9 Meters Biopharma in Q3 2021 and held it in 5 quarters.
  • Carnegie Investment Counsel's 9 Meters Biopharma position peaked at $13K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Carnegie Investment Counsel's 13F filing for Q4 2022, filed 24 Jan 2023.